Article thumbnail

Mechanism of HCV's resistance to IFN-α in cell culture involves expression of functional IFN-α receptor 1

By Sibnarayan Datta, Sidhartha Hazari, Partha K Chandra, Maria Samara¹, Bret Poat, Feyza Gunduz, William C Wimley, Hansjorg Hauser, Mario Koster, Christophe Lamaze, Luis A Balart, Robert F Garry and Srikanta Dash


The mechanisms underlying the Hepatitis C virus (HCV) resistance to interferon alpha (IFN-α) are not fully understood. We used IFN-α resistant HCV replicon cell lines and an infectious HCV cell culture system to elucidate the mechanisms of IFN-α resistance in cell culture. The IFN-α resistance mechanism of the replicon cells were addressed by a complementation study that utilized the full-length plasmid clones of IFN-α receptor 1 (IFNAR1), IFN-α receptor 2 (IFNAR2), Jak1, Tyk2, Stat1, Stat2 and the ISRE- luciferase reporter plasmid. We demonstrated that the expression of the full-length IFNAR1 clone alone restored the defective Jak-Stat signaling as well as Stat1, Stat2 and Stat3 phosphorylation, nuclear translocation and antiviral response against HCV in all IFN-α resistant cell lines (R-15, R-17 and R-24) used in this study. Moreover RT-PCR, Southern blotting and DNA sequence analysis revealed that the cells from both R-15 and R-24 series of IFN-α resistant cells have 58 amino acid deletions in the extracellular sub domain 1 (SD1) of IFNAR1. In addition, cells from the R-17 series have 50 amino acids deletion in the sub domain 4 (SD4) of IFNAR1 protein leading to impaired activation of Tyk2 kinase. Using an infectious HCV cell culture model we show here that viral replication in the infected Huh-7 cells is relatively resistant to exogenous IFN-α. HCV infection itself induces defective Jak-Stat signaling and impairs Stat1 and Stat2 phosphorylation by down regulation of the cell surface expression of IFNAR1 through the endoplasmic reticulum (ER) stress mechanisms. The results of this study suggest that expression of cell surface IFNAR1 is critical for the response of HCV to exogenous IFN-α

Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). AJ: Novel robust hepatitis C virus mouse efficacy model. Antimicrob Agents Chemother
  2. (1998). Albrecht JK: Interferon alpha-2b alone or combinantion with ribavirin as initial treatment for chronic hepatitis C. New Eng J Med
  3. (2003). CL: Viral Hepatitis C. Lancet
  4. (1998). Definition of the Interferon alpha receptor-binding domain on the Tyk2 kinase.
  5. (1992). Detection of hepatitis C virus RNA sequences by polymerase chain reaction in fixed liver tissue. Mod Pathol
  6. (1999). Dynamic redistribution of Stat1 protein in IFNsignaling visualized by GFP fusion proteins.
  7. (2008). Fuchs SY: Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylationdependent degradation of the type I interferon receptor. Cell Host and Microbe
  8. (2005). Functional cartography of the ectodomain of the type I interferon receptor subunit IFNAR1.
  9. (2006). Global challenges in liver disease. Hepatology
  10. (1994). Goodbourn S: The beta-interferon promoter responds to priming through multiple independent regulatory elements.
  11. (2008). Hadziyannis SJ: Old and merging therapies in chronic hepatitis C: an update. J Viral Hepat
  12. (2007). Hertzog PJ: Type I interferon receptors: Biochemistry and Biological functions.
  13. (2004). Identification of residues of the IFNAR1 chain of the type I human interferon receptor is critical for ligand binding and biological activity. Biochemistry
  14. (2010). Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. Virol J
  15. (2010). Induction and evasion of innate antiviral response by hepatitis C virus.
  16. (1997). Kinase-deficient forms of Jak-1 and Tyk2 inhibit interferon alpha signaling in a dominant manner.
  17. (2009). Lamaze C: Palmitoylation of interferon-alpha (IFN-α) receptor subunit IFNAR1 is required for the activation of Stat1 and Stat2 by IFN-alpha.
  18. (1998). Masaaki K: Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection.
  19. (2005). Mechanisms of type-I and type-II interferon-mediated signaling. Nat Rev Immunol
  20. (2009). N: Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol Res
  21. (2005). N: Interferon resistance of hepatitis C virus replicon-harbouring cells is caused by functional disruption of type 1-interferon receptors.
  22. (2010). N: Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat
  23. (2004). Okita K: Type 1 interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. J Viral Hepat
  24. (2005). Rehermann T: Acute Hepatitis C: a multifaceted disease. Semin Liv Dis
  25. (2005). S: Activation of interferon stimulated response element in a Huh-7 cell line replicating hepatitis C virus subgenomic RNA. Intervirology
  26. (2007). S: Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon. Virol J
  27. (2003). S: The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression.
  28. (2009). Seeff LB: Diagnosis, management, and treatment of hepatitis C: An update. Hepatology
  29. (2007). Shiratori Y: Intrahepatic mRNA levels of type I interferon receptor and interferon stimulated genes in genotype 1b chronic hepatitis C. Intervirology
  30. (2005). Sun X: Expression of interferon-alpha/beta receptor protein in liver of patients with hepatitis C virus -related chronic liver disease.
  31. (2010). Virahep-C Study Group: Contribution of genome-wide HCV genetic differences to outcome of interferon based therapy in Caucasian American and African American Patients. PloS One